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ABSTRACT 
Introduction: Pancreatic cancer is the fourth leading cause of cancer-related death 
among males and females in the United States. Sel-1-like (SEL1L) is a putative tumor 
suppressor gene that is downregulated in a significant proportion of human pancreatic 
ductal adenocarcinoma (PDAC). It was hypothesized that SEL1L expression could be 
down-modulated by somatic mutation, loss of heterozygosity (LOH), CpG island 
hypermethylation and/or aberrantly expressed microRNAs (miRNAs).  
Material and methods: In 42 PDAC tumors, the SEL1L coding region was amplified 
using reverse transcription polymerase chain reaction (RT-PCR), and analyzed by 
agarose gel electrophoresis and sequenced to search for mutations. Using fluorescent 
fragment analysis, two intragenic microsatellites in the SEL1L gene region were 
examined to detect LOH in a total of 73 pairs of PDAC tumors and normal-appearing 
adjacent tissues. Bisulfite DNA sequencing was performed to determine the 
methylation status of the SEL1L promoter in 41 PDAC tumors and 6 PDAC cell lines. 
Using real-time quantitative PCR, the expression levels of SEL1L mRNA and 7 
aberrantly upregulated miRNAs that potentially target SEL1L were assessed in 42 
PDAC tumor and normal pairs. Statistical methods were applied to evaluate the 
v 
 
correlation between SEL1L mRNA and the miRNAs. Further the interaction was 
determined by functional analysis using a molecular biological approach.  
Results: No mutations were detected in the SEL1L coding region. More than 50% of 
the samples displayed abnormally alternate or aberrant spliced transcripts of SEL1L. 
About 14.5% of the tumors displayed LOH at the CAR/CAL microsatellite locus and 
10.7% at the RepIN20 microsatellite locus. However, the presence of LOH did not 
show significant association with SEL1L downregulation. No methylation was 
observed in the SEL1L promoter. Statistical analysis showed that SEL1L mRNA 
expression levels significantly and inversely correlated with the expression of hsa-mir-
143, hsa-mir-155, and hsa-mir-223. Functional analysis indicated that hsa-mir-155 
acted as a suppressor of SEL1L in PL18 and MDAPanc3 PDAC cell lines.  
Discussion: Evidence from these studies suggested that SEL1L was possibly 
downregulated by aberrantly upregulated miRNAs in PDAC.  Future studies should be 
directed towards developing a better understanding of the mechanisms for generation 
of aberrant SEL1L transcripts, and further analysis of miRNAs that may downregulate 
SEL1L. 
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1 
BACKGROUND 
 
1. Pancreatic cancer 
The pancreas is an organ which has both endocrine and exocrine components. 
The endocrine component secretes hormones into the blood. Microscopically, the 
endocrine pancreas is made of cell clusters called islets of Langerhans which consist 
of five types of cells: alpha cells, beta cells, delta cells, PP cells and epsilon cells. 
Acinar cells of the exocrine pancreas produce and secret digestive enzymes and 
pancreatic juice (an alkaline fluid) into the small intestines through the exocrine ducts. 
Pancreatic cancer usually arises from the exocrine portion of pancreas [1]. 
In the United States, pancreatic cancer is the fourth leading cause of cancer-
related death among males and females. “The American Cancer Society's most recent 
estimates for pancreatic cancer in the United States for 2010 are: about 43,140 new 
cases (21,370 men and 21,770 women), and about 36,800 deaths (18,770 men and 
18,030 women). The lifetime risk for developing pancreatic cancer is about 1 in 71 
(1.41%), which is about the same for both men and women.” Tobacco smoking, 
family history of pancreatic cancer, personal history of pancreatitis, diabetes and 
obesity are all commonly recognized risk factors for this type of cancer [2]. Since the 
symptoms of pancreatic cancer are non-specific and varied, usually by the time it is 
diagnosed local or distant metastasis has already occurred. Prognosis for this disease is 
very poor with a median survival time of less than 6 months for all patients diagnosed 
with this disease, and the overall 5-year survival is only 6% [3]. The most common 
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form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which 
accounts for >75% of all pancreatic tumors [4].  
Histologically, PDAC is an invasive malignant epithelial neoplasm with no 
predominant component of any of the other carcinoma types. The appearance and 
arrangement of the PDAC cells present a duct-like structure instead of the 
predominant acinar cell structure seen in normal pancreas. “The degree of gland (duct) 
formation can vary from well-formed glands, to partially formed glands, to focal 
intracellular mucin production by poorly oriented cells infiltrating singly, to solid 
sheets of neoplastic cells.” [5] Although PDAC has a ductal morphology, there is no 
formal proof demonstrating that it originates from the ductal compartment.  
Acinar-to-ductal metaplasia has been implicated in the generation of pancreatic 
cancer precursor lesions known as pancreatic intraepithelial neoplasia (PanIN) [6-8]. 
Metaplasia is defined as a predominant cell type in a tissue being replaced by another 
cell type. There is evidence for at least two pathways for development of acinar-to-
ductal metaplasia. In the first, abnormal acinar cells transdifferentiate to ductal cells 
and then proliferate. In the second, ductal cells proliferate and the abnormal acinar 
cells undergo apoptosis.  
Animal models have been used to study the process of acinar-to-ductal 
metaplasia. Guerra et al. selectively expressed K-RASG12V in mice embryonic cells of 
the acinar/centroacinar lineage and observed the formation of PanIN lesions and 
invasive PDAC [9]. Similarly, Habbe et al. reported that knockin of the K-RASG12D 
allele in mature acinar cells of adult mice resulted in spontaneous induction of murine 
PanIN lesions of all histological grades [10]. By performing murine pancreatic 
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epithelial explants, Dr. Leach’s group showed spontaneous acinar-to-ductal metaplasia 
in response to EGFR signaling. The transdifferentiated cells simultaneously express 
both acinar and ductal markers [11]. 
In summary, all these models provided evidence that the genetic signature of 
pancreatic cancer involves genetic alterations in PanIN lesions that may induce acinar-
to-ductal cell transdifferentiation and further development into PDAC.  
 
2. Genetic alterations in the pathogenesis of PDAC 
Many allelic alterations have been seen in PDAC, including losses of 1p, 9p, 
12q, 17p, 18q and gain of 20q [12-18]. Several of these have been demonstrated to be 
involved in the progression of PDAC. The early genetic changes include the aberrant 
activation of the epidermal growth factor receptor (EGFR), erbB2 (HER2), v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (K-Ras), and the inactivation of Cyclin-
dependent kinase inhibitor 2A (CDKN2A/p16-INK4A) and alternative reading frames 
of the INK4A (ARF) tumor suppressor proteins [19-21]. Loss of two tumor 
suppressors, TP53 (p53) and BRCA2, frequently occur in the progression of the 
pancreatic intraepithelial neoplastic (PanIN) lesions. Loss of SMAD4/DPC4 function 
occurs at later stages [19, 20]. Overexpression of various components of Hedgehog 
(Hh) signaling including Shh and Ihh also have been seen in PanIN lesions as well as 
invasive PDAC [22-24]. An oncogenic serine/threonine kinase, AURKA, also showed 
overexpression in PDAC [25, 26]. The 9p21 region harbors the p16-INK4A gene; the 
17q13 region harbors the p53 gene; the SMAD4 gene is located on chromosome 18q21 
and AURKA maps to chromosome 20q13. Therefore, allelic loss or gain may explain 
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some of the gene expression alterations. Many signaling pathways can be affected by 
the above genetic abnormalities, such as the EGFR signaling pathway, the Ras 
signaling pathway, the transforming growth factor-beta (TGFβ) signaling pathway, as 
well as the Hedgehog (Hh) pathway and the Wnt–β-catenin cascades [27].  
However, all the above genetic alterations have also been observed in many 
other kinds of cancers, so unfortunately none of these serve as PDAC tumor specific 
biomarkers. 
 
3. SEL1L gene and PDAC 
Seven genes were identified in Dr. Killary’s laboratory, which were found to 
be differentially expressed in PDAC across three platforms. Products of these genes 
could serve as candidate biomarkers for PDAC [28]. One of the genes, SEL1L, has 
been shown to be abundantly expressed specifically in pancreatic tissues from healthy 
adult humans [29, 30]. Biunno et al. reported that SEL1L messenger RNA (mRNA) 
was not detected in 17% of PDAC tumors by reverse-transcription polymerase chain 
reaction (RT-PCR) [29]. Downmodulation or absence of SEL1L protein has been seen 
in 36% of human PDAC cases by immunohistochemistry. Immunohistochemical 
staining revealed that SEL1L protein is highly expressed in normal pancreatic acinar 
and islet cells, whereas it is not expressed in normal ductal cells [31]. Therefore, a 
question was raised that whether SEL1L downregulation was caused by the difference 
in cell types between normal pancreas and PDAC tumors. To answer this question, 
understanding the cellular origin of PDAC is a key. Acinar to ductal 
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transdifferentiation in some model systems suggests that acinar cells may be the cell of 
origin, and this may explain why SEL1L is expressed in some PDACs.  
SEL1L has been shown to modulate the expression of certain cancer-related 
proteins. In C. elegans, sel-1 has been identified as a negative regulator of the lin-
12/Notch family oncoproteins, lin-12 and glp-1. This is likely through its function in 
protein degradation [32, 33]. Overexpression of SEL1L in stably transfected PDAC 
cells and in nude mice caused a decrease in the aggressive behavior of the tumor cells, 
suggesting that SEL1L plays a tumor-suppressive role in the progression of PDAC 
[31]. Overexpression of SEL1L in PDAC cells also showed a significant increase in 
the expression level of the tumor suppressors Smad4, activin A, TIMP1, TIMP2, and 
PTEN, suggesting an interaction of SEL1L with the TGFβ and PTEN signaling 
pathways [31, 34].  
 
4. SEL1L gene and SEL1L protein                                                   
The homo sapiens SEL1L gene is located on chromosome 14q24.3-q31 with a 
length of 60967 base pairs (bp). It consists of 21 exons and the corresponding full 
length mRNA contains 6593 bp and the coding region is 2385 bp long. According to 
the gene annotations in the AceView database, National Center for Biotechnology 
Information (NCBI), the SEL1L gene produces 10 different transcripts that potentially 
encode 8 different isoforms [35].  
At the N terminus of the SEL1L protein, there is an XXRR-like ER 
(endoplasmic reticulum) membrane retention signal, and a proline, glutamic acid, 
serine, and threonine peptide (PEST) sequence which is known to target proteins for 
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rapid degradation. The SEL1L protein also contains a fibronectin type II domain 
which is a collagen-binding domain, three SEL-1-like sequence clusters in tandem 
which are predicted to function in protein-protein interaction, one highly conserved 
Hrd3-like motif which also has predicted function in protein binding, one 
transmembrane domain, and one proline-rich tail which may bring proteins together. 
Hrd3 is a protein of the ER membrane that plays a central role in ER associated 
protein degradation (ERAD). The Hrd3 protein motif is shared with several other 
proteins [36, 37]. From the protein structure, SEL1L is predicted to be an ER 
membrane protein with functions of protein-protein interaction and protein 
degradation. It has been reported that the region of SEL1L spanning amino acids 659 
to 794 containing the Hrd3-like motif, the transmembrane domain and the proline-rich 
tail is required for tumor growth inhibition [38]. 
 
5. SEL1L and UPR/ERAD pathway 
The human homolog of SEL1L has been recognized as a component of the 
“unfolded protein response/endoplasmic reticulum associated protein degradation 
(UPR/ERAD) pathway” [36, 39, 40]. The pancreas is an organ that produces many 
important proteins, such as insulin, glucagon and digestive enzymes [1]. Endoplasmic 
reticulum is an organelle found in all eukaryotic cells which functions in protein 
translation, folding, export and secretion [41]. Therefore, the ER is a critical organelle 
for synthesis and secretion of the many proteins made in the pancreas.  
Certain pharmacological or physiological conditions such as hypoxia, redox or 
glucose starvation, may lead to an accumulation of unfolded or misfolded proteins in 
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the lumen of the ER and cause ER stress. The UPR/ERAD pathway is triggered in 
response to the stress and induces the activation of several additional signaling 
pathways to promote long-term stress adaptation or apoptotic cell death [42].  
Figure 1 shows a simplified version of the URP/ERAD pathway. The primary 
function of this pathway is to maintain ER homeostasis and produce cell survival after 
stress. When this pathway is activated, the ER chaperone glucose-regulated protein 78 
(GRP78), the serine/threonine kinase Akt, the nuclear factor NF-κB, and the anti-
apoptosis factor Bcl-2/xL are induced [43-49]. Consequently, cell proliferation and 
angiogenesis are promoted. Simultaneously, the E3 ubiquitin-protein ligase HMG-
CoA reductase degradation protein 1 (HRD1) and SEL1L are also induced by the ER 
stress. SEL1L interacts with and stabilizes HRD1, and also recognizes misfolded 
proteins and transfers them into the cytosol for degradation [37-39]. On the other 
hand, when the accumulated unfolded proteins exceed a threshold above which the ER 
stress can no longer be controlled, the cell becomes committed to apoptosis through 
another part of the UPR pathway. Gadd153/CHOP is the dominant ER chaperone that 
is induced [50]. Caspase-4, a caspase responding only to ER stress and not to other 
signals, is activated [51]. When SEL1L expression was knocked down in mouse 
pancreatic β-cells, a decrease in cell growth was observed.  This may be through 
activation of the apoptosis pathway described above [52].           
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Figure 1. Unfolded protein response/endoplasmic reticulum associated protein 
degradation (UPR/ERAD) pathway. Green: survival pathway; pink: apoptosis 
pathway. 
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6. The goals of this study 
So far neither mutations nor genomic alterations have been reported for SEL1L 
which is a putative tumor suppressor in PDAC. The goals of this study were to 
investigate the molecular mechanisms of SEL1L downregulation, and to better 
understand the role of SEL1L in the pathogenesis of PDAC. I hypothesized that 
SEL1L expression could be down-modulated by somatic mutation, loss of 
heterozygosity (LOH), CpG island hypermethylation and/or aberrantly expressed 
microRNAs (miRNAs). Results from this study provide a better understanding of the 
abnormalities of the SEL1L gene in PDAC, which may lead to the discovery of PDAC 
tumor specific biomarkers or the development of new prevention and treatment 
strategies for this dismal disease. 
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Chapter 1 
 
SEL1L Gene Mutation Study 
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1.1 Introduction 
Due to genetic instability, cancer cells often carry somatic mutations in either 
tumor suppressor genes or oncogenes. Somatic mutations occurring at the splice sites 
or exonic splicing enhancers may cause aberrant transcription, and may lead to the 
translation of aberrant proteins. Mutations occurring at the coding region of a gene 
may also produce aberrant proteins, which may influence the function of the gene. 
Mutations in some predominant cancer-related genes have been frequently reported in 
PDAC tumors. For example, Kras mutations are some of the earliest events in the 
tumorigenesis of PDAC, which have been detected in 90% of PDACs with most of the 
mutations occurring at codon 12, 13, and 61; loss of the p53 gene often occurs later in 
the development of pancreatic neoplasia, generally by missense alterations of the 
DNA-binding domain in more than 50% of PDACs [18-20].  
So far, only one study of SEL1L gene alterations in PDAC has been conducted. 
In this study Southern blotting was performed on 17 neoplastic cases, but no gross 
genomic alterations were observed [28]. The Southern blotting method uses probe 
hybridization to identify a restriction fragment of a gene. However, in this report the 
authors did not give the exact region that they examined, and apparently they did not 
examine the whole gene region of SEL1L. Their results might not give an accurate 
conclusion, and it is still important to determine if somatic mutations are present in the 
SEL1L gene. Therefore, I chose to examine SEL1L for mutation in PDAC samples. 
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1.2 Materials and Methods 
 
Materials  
PDAC tumors and the matched normal-appearing adjacent pancreatic tissue 
specimens were collected from surgical resections performed at The University of 
Texas M. D. Anderson Cancer Center (UTMDACC) before patients were treated with 
chemotherapy or radiotherapy. The identification of normal adjacent tissue was based 
on microscopical observations from the pathologist analyzing the tissue. All the 
tissues were stored in -80ºC freezers prior to RNA/DNA extraction. A total of 42 
tumor/normal pairs were examined in this study. A quality check of integrity with the 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) indicated that the RNA 
samples did not display degradation.  
 
Extraction of RNA and DNA 
Total RNA was extracted using the miRNeasy Mini Kit according to the 
manufacturer’s instructions (Qiagen, Valencia, CA). DNA was extracted from the 
inter-phase and phenol phase after RNA isolation. The isolation procedures followed 
the TRIzol Reagent protocol (Invitrogen, Carlsbad, CA). DNA and RNA 
concentrations were measured with a NanoDrop spectrophotometer (Thermo 
Scientific, Wilmington, DE).  
 
Reverse transcription polymerase chain reaction (RT-PCR) and sequencing 
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The High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
Foster City, CA) were used for complementary DNA (cDNA) synthesis. The 
conversion to cDNA started from 1ug of total RNA in a single 20µL reaction using 
random primers. To amplify the cDNA with high fidelity, three sets of primers were 
used for the entire coding region of SEL1L, and the RT-PCR products overlapped one 
another by about 100 bp. 
The SELmRNA-1 primer set generates a product of 934 bp which extends 
from SEL1L exon 1 to 7. SELmRNA-2 generates a 972 bp product which is from exon 
6 to 17. SELmRNA-3 amplifies exon 16 to 21 and the product size is 987 bp. 
Sequences and locations of the primers were shown in Figure 2. The reactions were 
carried out in a final volume of 30 uL of a mixture containing 2µL of cDNA, 10 pmol 
of each primer, deoxynucleotide triphosphates (dNTP, each at 0.25 mM), KCl (50 
mM), MgCl2 (1.5 mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of AmpliTaq Gold 
DNA polymerase (Applied Biosystems). The same thermal cycling conditions were 
applied to all 3 reactions: denaturation at 95°C for 5 minutes for 1 cycle, followed by 
40 cycles at 95°C for 45 seconds, 56°C for 45 seconds, 72°C for 45 seconds, and then 
an extension of 72°C for 7 minutes. A 5 uL aliquot of the RT-PCR products was run 
through 1% agarose gel (Phenix Research Product, Candler, NC) using 100 bp DNA 
ladder as a molecular weight marker (Invitrogen). The remainder of the products were 
purified with QIAquick PCR Purification Kit (Qiagen), and then sequenced in the 
DNA Analysis Facility at UTMDACC using ABI PRISM 3730 DNA sequencers 
(Applied Biosystems).  
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A.  
 
B. 
 
 
 
Figure 2. Sequences and locations of the primers for SEL1L coding region 
mutation study. The rectangular boxes in figure B represent the exons in SEL1L 
cDNA. Translation start site and stop site were indicated. F1 and R1 indicate the 
locations of forward and reverse primers of SELmRNA-1; F2 and R2 are SELmRNA-
2; F3 and R3 are SELmRNA-3. 
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1.3 Results 
 
Altered SEL1L transcripts in PDAC tumors and paired normal-appearing adjacent 
tissues  
When reverse-transcribed mRNAs were amplified using the SELmRNA-1 
primer sets, agarose gel electrophoresis revealed that in addition to the predicted RT-
PCR products, some weaker products with smaller sizes were present. These smaller 
products were observed in both PDAC tumor tissues and normal-appearing adjacent 
tissues. This phenomenon was not observed when the cDNAs were amplified using 
the SELmRNA-2 and SELmRNA-3 primer sets. The representative results from 7 
tumor/normal pairs are shown in Figure 3. When the RT-PCR was repeated using the 
SELmRNA-1 primers, although additional products were observed again, different 
patterns of products were present. From the results of two independent RT-PCR 
amplifications, additional products were identified in more than half of the samples.  
Because most of the unexpected small products had much lower intensities, 
nucleotide sequence analysis usually displayed only the sequence of the 
predominating normal products. However, in a few of the samples one smaller product 
showed competitive intensity compared to the expected product. Sequencing 
chromatograms of these samples showed identifiable double peaks, so that the 
sequence of both products could be analyzed. Figure 4 shows such a chromatogram 
displaying the out of phased sequence indicating deletions.  
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Figure 3. Agarose gel electrophoresis of representative RT-PCR products of 
SEL1L coding region. M, marker. T, PDAC tumor. N, normal-appearing pancreatic 
tissue. Specimens from the same patient have the same number. Names of primer sets 
are noted at the right.  
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Figure 4. A sequencing chromatogram displays double peaks. The RT-PCR 
products of a PDAC tumor sample were produced using SELmRNA-1 primers. The 
out-of-phase sequence starts at position 157 and extends to position 360, indicating the 
existence of two products in this sample.  
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Figure 5 shows SEL1L mRNA RT-PCR products from 5 representative 
samples. In Figure 5A, using agarose gel electrophoresis, multiple different products 
with competitive intensities can be identified in the 5 samples. Figure 5B 
schematically presents a diagram of the sequencing results of the full-length (FL) 
normal product and the small aberrant products. The 497bp fragment in sample 1 
skipped exons 4, 5, and 6 and potentially encodes a truncated protein of 125 amino 
acids (aa). In sample 2, exon 3 was skipped and a stop codon was introduced in exon 4 
so that a protein of 37 aa could be generated. The sequence of the 871-bp fragment in 
sample 3 showed that 63 bp from the beginning of exon 4 was spliced through a novel 
AG splice acceptor site. The predicted amino acid sequence is in-frame with 21 aa 
deleted.  In the 293-bp fragment of sample 4, a non-conserved donor site in exon 2 
was joined to a non-conserved acceptor site in exon 6. Both the donor and acceptor 
contain a 7-base sequence of AGGCAGC. The frameshift of this fragment would 
produce a 32-aa truncated protein.  Similar aberrant splicing happened in sample 5 as 
was seen in sample 4. The splicing donor site in sample 5 was the same as in sample 
4, but the acceptor site was at a different location in exon 6. A 46-aa protein would be 
encoded.  
These sequencing results indicated that the smaller products arose as a result of 
mis-splicing of the SEL1L pre-mRNA, but none of these products are included in the 
NCBI transcription annotation database (AceView). This database is supposed to 
provide a comprehensive and non-redundant sequence representation of all public 
mRNA sequences [33]. Commonly, mis-splicing occurring at intron-exon boundaries 
is referred to as alternate splicing; and splicing occurring at cryptic splice sites (within 
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intron or exon) is referred to as aberrant splicing. Here, samples 1, 2, and 3 showed 
alternate splicing, and samples 4 and 5 showed aberrant splicing. 
Mis-splicing could be caused by mutations at the splicing sites. Therefore, of 
the 5 samples in Figure 5, polymerase chain reaction (PCR) products of the genomic 
sequences flanking the intron-exon boundaries and the non-conserved splicing sites 
were generated. No mutations were detected (data not shown here), indicating that the 
alteration of SEL1L splicing was not caused by genomic mutations. 
 
Mutation is not detected in the SEL1L coding region 
The sequence of the whole SEL1L coding region was determined for cDNA 
generated from 42 PDAC tumor samples and compared to the SEL1L coding sequence 
reported in Genbank using the BLAST computer algorithm [53], but no mutations 
were detected in any of them. Several single nucleotide polymorphisms (SNPs) were 
identified in the sequences that have been listed in the NCBI dbSNP database, 
including rs11499034 located in exon 4 in 1 sample, rs11851475 in exon 17 in 1 
sample, and rs1051193 in exon 20 in 2 samples. The frequencies of these SNPs were 
close to the reported frequencies in the NCBI database in the normal population of 
Caucasians, indicating that these SNPs are normally present. 
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Figure 5. Alteration of SELmRNA-1 RT-PCR products in 5 PDAC tumors.  
A. Agarose gel electrophoresis. M, marker. B. Schematic diagram of the smaller 
products in relation to the full-length fragment. FL, full-length (expected product). A 
broken line in an exon indicates an incomplete exon. Each rectangular box represents 
one exon. Arrows indicate the locations of stop codon for protein translation. RT-PCR 
product sizes are noted at the right. 
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1.4 Discussion 
In this study, I investigated whether genetic mutations exist in the pancreas-
specific putative tumor suppressor gene SEL1L in PDAC cases, and whether mutations 
are the cause of SEL1L downregulation. By amplifying and sequencing the coding 
region of SEL1L in 42 pairs of PDAC tumors and normal adjacent tissues, no 
mutations were detected; interestingly, however, unexpected altered splice forms of 
SEL1L pre-mRNA were observed. 
Sequencing results revealed that these RT-PCR products were true SEL1L 
transcripts that were not generated from PCR artifacts or wrong priming. The 
unexpected splicing products that were observed were different from the normal 
SEL1L alternate transcripts that are annotated in the NCBI database. These unexpected 
SEL1L RT-PCR products had weak intensities on agarose gels, and the exact patterns 
were not reproducible. This lack of reproducibility is likely due to a low abundance of 
any given aberrant splice product.  
The formations of the alternate/aberrant splice products shown in Figure 5 
suggest that the splicing alterations of SEL1L most likely occur between exon 2 to 
exon 6. The protein sequence corresponding to this region involves a PEST sequence, 
a Fibronectin Type II (FNII) domain, and a SEL-1-like repeat. The predicted truncated 
SEL1L proteins missing these specific domains would lose their function in protein 
modulation. It is also possible that the dysfunctional proteins interrupt the tumor-
suppressor function of normal SEL1L protein through a competition for target protein 
binding.  
  
22 
The same mis-splicing phenomena have been previously reported in other 
tumor suppressor genes in various cancers, such as tumor susceptibility gene 101 
(TSG101) in breast and lung cancer [54, 55], Mdm2 p53 binding protein homolog 
(MDM2) in ovarian, bladder, and breast cancer [56-58], and fragile histidine triad gene 
(FHIT) in breast, head and neck, and lung cancers [59-61]. In PDACs, abnormal 
transcripts have been observed in cholecystokinin-B/gastrin receptor (CCKBR) [62] 
and Mucin type 4 (MUC4) [63].  
Similar to what has been seen for the TSG101, MDM2 and FHIT genes, 
abnormal products in normal-appearing tissues adjacent to the tumor were observed. 
One reason could be due to the fact that the PDA tumor/normal paired tissue samples 
were obtained without using precise microdissection techniques. Therefore, the 
normal-appearing samples could be contaminated with some tumor cells, or there may 
have been a field effect in the normal-appearing tissue that was in close proximity to 
the tumor, or there could have been micrometastasis to normal-appearing pancreatic 
tissue.  
As has been reported for those genes mentioned above, I determined that the 
aberrant SEL1L splicing was also not caused by genomic DNA sequence alterations. 
Aberrant expression of splicing factors may be the mechanism for the mis-splicing. 
For instance, a core splice regulatory protein serine-arginine protein kinase 1 (SRPK1) 
has shown up-regulation in pancreatic carcinomas [64]. Aberrant splicing factors may 
cause binding to (or failure to bind to) splice enhancers located in the SEL1L gene 
regions. This could explain why mis-spliced products were observed from the RT-
PCR using SELmRNA-1 primers but not SELmRNA-2 and -3 primers. The increase 
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in aberrant splicing could also be caused by the changes of environmental factors, 
such as elevated temperature and low pH that are frequent occurrences in tumor 
tissues. A study of the tumor suppressor genes neurofibromatosis type 1 (NF-1), 
neurofibromatosis type 2 (NF-2), and tuberous sclerosis 2 (TSC-2) conducted by Dr. 
Kaufmann et al. suggested that the environmental alterations might change the 
structures at the splice donor site and disturbed splicing [65].  
Elela and colleagues [66, 67] used high-throughput RT-PCR and deep 
sequencing to analyze the alternative splicing profiles of cancer-associated genes in 
normal and tumor tissues for both ovarian and breast cancer. They found that certain 
alternative splicing events significantly differed in the tumors relative to normal 
tissues. However, the method that was used in this study could not provide a full view 
of the alternative splicing events in the samples analyzed. Lukas et al. reported that the 
presence of the aberrant splicing products of MDM2 in breast cancer specimens was 
correlated with a shorter overall patient survival [58]. Their results suggest that 
aberrant splicing in a tumor suppressor gene could be of clinical importance for cancer 
patients.  
To determine whether there are tumor-specific SEL1L transcripts in PDAC, 
further tests with microdissected tissues and deep sequencing are necessary. Also 
because of the limitation of the material and methods used in this study, I was unable 
to determine whether mis-splicing was associated with the altered expression of 
SEL1L in PDAC. 
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Chapter 2 
 
Loss of Heterozygosity in the SEL1L Gene 
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2.1 Introduction 
Loss of heterozygosity (LOH) is defined as the loss of one allele in a tumor at 
a constitutionally heterozygous locus, and indicates loss of detection of one of the two 
alleles at that locus. LOH can arise via several pathways, including deletion, gene 
conversion, mitotic recombination, chromosome loss and amplification of one allele 
[68]. When there is only one functional allele left on the other chromosome, the 
product of a gene with LOH may be reduced, and it may not be expressed at levels 
sufficient to permit the cell to function normally. LOH is a common occurrence in 
cancer. In pancreatic adenocarcinomas, such allelic loss has been frequently observed 
at chromosome 9p which contains the p16 gene, 17p which contains the p53 gene, and 
18q which harbors SMAD4 [11, 69].  
Microsatellites are good markers for LOH studies. Microsatellites are short 
tandem repeats of DNA that are distributed throughout the genome. The number of 
repeats often varies between two alleles, providing a high frequency of allelic 
heterozygosity. Two polymorphic intragenic microsatellites containing cytosine-
adenine (CA) repeats in the SEL1L gene in the Italian population have previously been 
described by Chiaramonte et al. CAR/CAL microsatellite is located in SEL1L intron2 
and was reported with a heterozygosity frequency of 0.68; RepIN20 microsatellite is 
located in intron20 with a heterozygosity frequency of 0.85 [70]. No other 
microsatellites have been found in the SEL1L gene locus. 
In this chapter, using these 2 microsatellite markers, I aimed to determine 
whether LOH is observed at the SEL1L gene locus in PDAC, and whether LOH 
correlates with the downregualtion of SEL1L. 
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 2.2 Materials and Methods 
 
Materials  
PDAC tumors and the matched normal-appearing adjacent pancreatic tissue 
specimens were collected as described in Chapter 1. A total of 73 pairs of DNA 
samples were tested in this study.  
 
Real-time quantitative PCR (qPCR)  
The expression levels of SEL1L mRNA were examined in the DNA Analysis 
Facility at UTMDACC. The TaqMan Gene Expression Assay kit targeting SEL1L 
(Applied Biosystems, Foster City, CA) were used for the assays. The assays were run 
using the 7900HT Fast Real-Time PCR System (Applied Biosystems). RNA from the 
matched normal-appearing adjacent tissue was used as a calibrator for the tumor. 
SEL1L mRNA expression was normalized to that of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). All of the assays were run in duplicate. The relative 
quantities (RQs) of mRNA or miRNA expression in the tumors were calculated as 
described by Livak and Schmittgen [71]. A gene was considered to be downregulated 
if RQ < 0.5 so that the gene expression in the tumor was less than half that in the 
normal-appearing adjacent tissue. A gene was considered to be upregulated if RQ > 2, 
which means that the gene expression in the tumor was more than twice that in the 
normal-appearing adjacent tissue.  
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Fluorescent fragment analysis 
This technique involves using fluorescent primers during amplification to label 
PCR products as described by Canzian et al [72]. Two kinds of fluorescent dyes HEX 
and FAM were used for labeling. Two sets of primers were designed for each of the 
microsatellite regions. The PCR amplifications were all carried out in a final volume 
of 30 µL of a mixture containing 10 ng of DNA, 10 pmol of each primer, 
deoxynucleotide triphosphates (dNTP) each at 0.25 mM, KCl (50 mM), MgCl2 (1.5 
mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of AmpliTaq Gold DNA Polymerase 
(Applied Biosystems, Foster City, CA).  
For the intron 2 microsatellite, the primers were as follows: CAR/CAL-1 
(forward 5′-HEX-AAA ATT ACT GAC CTA CAA GAG GG-3′ and reverse 5′-TGG 
GCT TGG TTA GTA CTT GG-3′). The reaction was started at 95°C for 5 minutes, 
followed by 40 cycles (95°C for 45 seconds, 55°C for 45 seconds, and 72°C for 45 
seconds) and then an extension of 72°C for 7 minutes. For another set of primers 
CAR/CAL-2 (forward 5′-FAM-AAA AGG ACA GAA AAA GAC AGA TGG-3′ and 
reverse 5′-GGG AGA GCT CAA TCA ACC AA-3′), the same PCR protocol was 
applied except that the annealing temperature was 58.5°C. For the intron 20 region, 
the primers were: REPIN20-1 (forward 5′-HEX-CGT ATT GGA TTA CTG GTG 
GAA AG-3′ and reverse 5′-GGC AAG GAA CTG GGA AAG TTA C-3′) with an 
annealing temperature of 58.5°C, and REPIN20-2 (forward 5′-FAM-GCC CCA GTG 
TTG TTT TGT TT-3′ and reverse 5′-AGG CAA GGA ACT GGG AAA GT-3′) with 
an annealing temperature of 60°C.  
  
28 
Using a 3730 DNA Analyzer (Applied Biosystems), the PCR products were 
separated by capillary electrophoresis and analyzed in the DNA Analysis Facility at 
UTMDACC. Fluorescently labeled fragments were detected by the machine and the 
lengths of the fragments and fluorescent signal strengths were determined by analysis 
software. In the case of heterozygotes, the fluorescent signal strength of the PCR 
products from constituent alleles between tumor and its paired normal tissue was 
compared. A ratio was calculated as follows: (tumor peak 1 / tumor peak 2) / (normal 
peak 1 / normal peak 2). The average ratio from both primer sets was counted as the 
final result. A ratio greater than 1.500 (3/2) or less than 0.667 (2/3) was considered as 
positive evidence for the presence of LOH in the tumor. For example, in Figure 6B, 
the ratio was calculated as: (16273 / 5684) / (12073 / 9278), which is 2.127 and 
indicates that LOH displays in this tumor sample.  
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2.3 Results 
 
LOH is detectable in a small proportion of the PDAC tumors 
Figure 6 shows representative results of the fluorescent fragment analysis. In 
Figure 6A, a normal-appearing adjacent tissue specimen shows a single-peak of 
fluorescence signal at the RepIN20 microsatellite locus indicating homozygosity for 
this marker. Normal samples that are homozygous at a particular microsatellite marker 
cannot provide information of allelic change in the tumor; therefore they were not 
scored for LOH. In Figure 6B, both the PDAC tumor and its normal-appearing 
adjacent tissue shows a double-peak at the CAR/CAL microsatellite locus indicating 
heterozygosity for this marker, and a partial loss of the second peak is observed in the 
tumor sample.  
As shown in Table 1, 8 out of 55 (14.5%) informative samples displayed LOH 
at the CAR/CAL locus, and 6 out of 56 (10.7%) informative samples displayed LOH 
at RepIN20. Of these, 4 samples displayed LOH at both loci. Totally LOH was seen in 
10 samples. Of the 73 PDAC tumor samples in this study, 8 were homozygous at both 
microsatellite loci, so that the LOH information was obtained from only 65 samples. 
In total, 10 out of 65 (15.4%) of these PDAC tumor samples displayed LOH at one or 
both loci. 
  
SEL1L LOH is not associated with its downregulation at the RNA level 
SEL1L qPCR results were available for only 49 out of the 65 informative 
sample pairs due to the quality of the corresponding RNA samples. In the group of 
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samples displaying SEL1L LOH (total n = 8), 5 samples presented with SEL1L 
downregulation and 3 samples presented with normal SEL1L expression. In the group 
of samples without LOH (total n = 41), 24 samples presented with SEL1L 
downregulation and 17 with normal SEL1L expression. Using Fisher’s exact test to 
evaluate the association between the presence of LOH in SEL1L gene region and the 
expression of SEL1L mRNA, LOH is not significantly associated with SEL1L 
downregulation (P = 0.300). 
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Figure 6. Chromatograms of fluorescent fragment analysis. Each peak has two 
labels: number in the upper box gives the length of the PCR fragment, and number in 
the lower box indicates the signal strength. A. Result for homozygous specimen. B. 
Heterozygosity in a tumor and in its paired normal-appearing adjacent tissue. Allelic 
loss can be seen at the second peak in the tumor.  
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2.4 Discussion 
In this study, LOH was detected at two SEL1L intragenic microsatellite loci 
(CAL/CAR and RepIN20) in 15.4% of the PDAC tumors (Table 1). Fluorescent 
fragment analysis results showed an imbalanced relative intensity rather than total loss 
of one allele. Because of the heterogeneity of cancer cells, it is possible that LOH is 
not displayed in every single tumor cell but only in a sub-population of the cells. Also, 
because the samples that were studied were not from tissue micro-dissection, the 
tumor samples may contain some non-tumor tissue. Therefore, this may explain a 
partial allelic loss in the cases displaying LOH.  
The results indicate that genome instability exists in the SEL1L gene region in 
a small portion of PDACs. Although it was not possible to determine the exact 
boundaries of the region of allelic loss by performing LOH analysis, the presence of 
LOH indicates that there is a genomic abnormality in the SEL1L gene region that 
could possibly lead to the production of aberrant SEL1L proteins.  
In this study, there was no evidence showing that LOH correlated with SEL1L 
mRNA downregulation. This may be because one functional allele is sufficient to 
maintain the normal expression of SEL1L. However, even if the expression level of 
SEL1L mRNA is normal, if aberrant SEL1L proteins are generated, they may 
competitively interrupt the binding of normal SEL1L protein to the unfolded proteins 
for degradation.  
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Chapter 3 
 
SEL1L CpG Island Methylation 
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 3.1 Introduction 
Gene promoter regions usually contain a cluster of cytosine-guanine 
dinucleotides (CpG) known as CpG islands. Hypermethylation of the cytosine residues 
in CpG sites may induce chromatin condensation and inhibit the binding of 
transcription factors, resulting in repression of gene expression [73, 74]. Aberrant CpG 
island methylation is a common epigenetic mechanism for transcriptional silencing of 
tumor suppressor genes [75]. Some of the most frequently reported genes that are 
silenced by DNA methylation include CDKN2A/p16-INK4 in lung cancer, colorectal 
cancer, and gastric carcinoma [76-78]; Ras association domain family 1 (RASSF1) in 
gliomas, lung cancer, and ovarian cancer [79-81]; and O6-methylguanine-DNA 
methyltransferase (MGMT) in lung cancer and colorectal cancer [82, 83]. Aberrant 
promoter methylation of p16-INK4 has been seen in 52% of PDAC cases [84]. Some 
other genes that have been found to display hypermethylation in PDAC include the 
multiple endocrine neoplasia I (MEN1) and serpin peptidase inhibitor B5 
(SERPINB5) [85, 86]. 
In this chapter, the goal was to determine whether hypermethylation 
contributes to SEL1L downregulation.  
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3.2 Materials and Methods 
 
Materials  
DNA was extracted from 41 PDAC tumors and 6 PDAC cell lines. Of the cell 
lines, MDAPanc3, MDAPanc28 and MDAPanc48A were established in our 
laboratory, and Panc-1, Capan-2 and AsPC-1 cell lines were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). 
  
Bisulfite DNA sequencing 
The bisulfite (BS) modification method is commonly used to determine the 
pattern of DNA methylation. Sodium bisulfite is a chemical compound with the 
chemical formula NaHSO3. It can deaminate cytosine into uracil, but does not affect 
the methylated form of cytosine with a methyl group attached to carbon 5 [87]. 
Therefore, the methylated and unmethylated cytosines can be distinguished from one 
another by using this method (Figure 7).  
DNA samples were treated with BS using the EZ DNA Methylation Gold Kit 
(Zymo Research, Orange, CA). The treatment started from 1ug of genomic DNA in a 
20µL reaction. The procedure was carried out according to the manufacturer’s 
instructions. The modified SEL1L promoter region was amplified by PCR, and the 
PCR products were subsequently analyzed by either pyrosequencing or Sanger 
sequencing. Universal methylated DNA and universal unmethylated DNA (Zymo 
Research) were used as controls to assess the efficiency of BS-mediated conversion 
for both sequencing methods. 
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For pyrosequencing, nested PCR reactions were performed. The first set of 
PCR primers was SEL1Lmeth1 (forward 5′-GTT GAA TTT AGG GGT TAT TAA 
TTA GTT GGG-3′ and reverse 5′-TTC TAA TCC AAT CAC CAT AAT CTC CC-3′); 
and the nested primers were SEL1Lmeth2 (forward 5′-ATT TAG GGG TTA TTA 
ATT AGT TGG GGT T-3′ and reverse 5′-biotin-AAA ATC ATT CAT TAA CCA 
ATC ATT ATA C-3′). The sequencing primer was SEL1LmethS (5′-TTA GTT GGG 
GTT ATG-3′). Four CpG sites were included in the analyzed sequence, and the 
methylation status of these sites was evaluated for 24 of the PDAC tumors and 6 cell 
lines using the PSQ HS96A system (Biotage, Foxboro, MA) and the allele 
quantification module.  
For Sanger sequencing, nested PCR was performed of the entire CpG island of 
SEL1L. The first set of primers was SEL1Lmeth3 (forward 5′-GAT GAG TTT TTT 
TTT TTT AGT TTT GGA TTT A-3′ and reverse 5′-TCC TAT ATC AAA ATT CAT 
TCC TTT AAA AT-3′), and the set of nested primers was SEL1Lmeth4 (forward 5′-
ATT TAG GGG TTA TTA ATT AGT TGG GG-3′ and reverse 5′-CAC TCC ACC 
TTC CTA AAT AAC C-3′). The PCR products were purified with a QIAquick PCR 
Purification Kit (Qiagen) and then sequenced in the DNA Analysis Facility at 
UTMDACC using ABI PRISM 3730 DNA sequencers (Applied Biosystems, Foster 
City, CA). SEL1Lmeth4 reverse primer was used as sequencing primer. With this 
sequencing method, the methylation status of the 6 PDA cell line and 17 PDAC tumor 
DNAs were evaluated.  
The PCR amplification was carried out in a final volume of 30 µL of a mixture 
containing 10 pmol of each primer, deoxynucleotide triphosphates (dNTP) each at 
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0.25 mM, KCl (50 mM), MgCl2 (1.5 mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of 
AmpliTaq Gold DNA Polymerase (Applied Biosystems). For the reactions using the 
first set of primers (SEL1Lmeth1 or SEL1Lmeth3), 2 ul of BS-treated DNA was 
added as template. For the reactions using the nested primers (SEL1Lmeth2 or 
SEL1Lmeth4), 1 ul of the PCR product from the first round was used as template. The 
reactions were started at 95°C for 5 minutes, followed by 40 cycles (95°C for 45 
seconds, proper annealing temperature for 45 seconds, and 72°C for 45 seconds) and 
then an extension of 72°C for 7 minutes. 
SEL1L CpG island sequences and locations of the primers are shown in Figure 
8. 
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A. 
 
 
 
B. 
 
Figure 7. Bisulfite sequencing for methylation detection.  
A. Bisulfite treatment flowchart (picture is modified from Zymo Research company 
website); B. Sequence after BS treatment at CpG site for methylated and unmethylated 
DNA. 
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ctgggaattgtagtctcggatgagcctctttctcccagtcttggactcacgcgctgattc 
TTGGGAATTGTAGTTTCGGATGAGTTTTTTTTTTTTAGTTTTGGATTTACGCGTTGATTT 
                          SEL1Lmeth3F 
cggttgaacccaggggctaccaattagctggggccatgtccgtgagtcgtggtccaaccg 
CGGTTGAATTTAGGGGTTATTAATTAGTTGGGGTTATGTTCGTGAGTCGTGGTTTAATCG 
 SEL1Lmeth1F SEL1Lmeth4F SEL1Lmeth2F 
agaaagctggtgtgggagcttcgtacaatgattggccaatgaatgacccccggggcggag 
AGAAAGTTGGTGTGGGAGTTTCGTATAATGATTGGTTAATGAATGATTTTCGGGGCGGAG 
                             SEL1Lmeth2R 
caatgggggtgggcggggagaccatggtgattggaccagaagcccgcgacggcgggcggg 
TAATGGGGGTGGGCGGGGAGATTATGGTGATTGGATTAGAAGTTCGCGACGGCGGGCGGG 
                      SEL1Lmeth1R 
gattggctgcgcgctgggtcagggaagcctgggaaggggcggaggaaggagactagagca 
GATTGGTTGCGCGTTGGGTTAGGGAAGTTTGGGAAGGGGCGGAGGAAGGAGATTAGAGTA 
 
ggaagagcagcggcgaggcggcggtggtggctgagtccgtggtggcagaggcgaaggcga 
GGAAGAGTAGCGGCGAGGCGGCGGTGGTGGTTGAGTTCGTGGTGGTAGAGGCGAAGGCGA 
 
cagctctaggggttggcaccggccccgagaggaggatgcgggtccggatagggctgacgc 
TAGTTTTAGGGGTTGGTATCGGTTTCGAGAGGAGGATGCGGGTTCGGATAGGGTTGACGT 
 
tgctgctgtgtgcggtgctgctgagcttggcctcggcgtcctcgggtcagtatccgcccc 
TGTTGTTGTGTGCGGTGTTGTTGAGTTTGGTTTCGGCGTTTTCGGGTTAGTATTCGTTTT 
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ctcgggctgaaggcccagagcctccgccccccagcctctacagccggcggggccgtgggg 
TTCGGGTTGAAGGTTTAGAGTTTTCGTTTTTTAGTTTTTATAGTCGGCGGGGTCGTGGGG 
 
actccaggctcgggaccccgttctccctgggcacatctcgcactgggctgtcactcgctc 
ATTTTAGGTTCGGGATTTCGTTTTTTTTGGGTATATTTCGTATTGGGTTGTTATTCGTTT 
 
tttggctttgcttggcctgcgccaaaggggctatttaggaaggtggagtggggtggaaaa 
TTTGGTTTTGTTTGGTTTGCGTTAAAGGGGTTATTTAGGAAGGTGGAGTGGGGTGGAAAA 
                                  SEL1Lmeth4R 
agaaggggcggtcaccctgcccacacctctctcccacgtaacaaactttgcgcgactctt 
AGAAGGGGCGGTTATTTTGTTTATATTTTTTTTTTACGTAATAAATTTTGCGCGATTTTT 
 
ctcacgaacgcggaattgactccaaaggaatgaatcctgatacaggagcccgagtggagc 
TTTACGAACGCGGAATTGATTTTAAAGGAATGAATTTTGATATAGGAGTTCGAGTGGAGT 
                          SEL1Lmeth3R 
 
Figure 8. SEL1L CpG island sequences and locations of BS PCR primers.  
Yellow highlight: SEL1L CpG island; Lower case: original sequence before BS 
treatment; Upper case: converted sequence after BS treatment; Underline: CpG site; Red 
rectangle: primers for BS pyrosequencing PCR; Blue rectangle: primers for BS Sanger 
sequencing PCR; Italic: SEL1LmethS. 
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3.3 Results 
 
Methylation is not detected in the SEL1L promoter CpG island 
BS sequencing results of the universal unmethylated control showed complete 
conversion of all the cytosine residues, and the universal methylated control showed 
conversion of all the cytosine residues except for those at the CpG sites. These results 
indicated that the BS treatment worked successfully and could detect the methylation 
status of SEL1L CpG island reliably. 
The BS pyrosequencing method examined 3 CpG sites with high fidelity in the 
SEL1L promoter region. All of the samples analyzed by this method presented with 
100% of thymine (T) and 0% of cytosine (C) at the covered CpG sites, which 
indicated a lack of methylation at these sites.  Sanger sequencing of BS-treated DNA 
also did not display evidence for methylation at the examined CpG sites in any of the 
samples. Representative results of both sequencing methods are shown in Figure 9. 
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A. 
 
B. 
 
  
Figure 9. Bisulfite sequencing results.  
A. Pyrosequencing chromatogram indicating that at all three CpG sites the cytosines 
were 100% unmethylated; D. Sanger sequencing chromatogram showing a sequence 
from reverse direction without methylation.  
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3.4 Discussion 
The advantage of the pyrosequencing method is that it is quantitative, so it was 
possible to determine if the levels of hypermethylation detected in the tumor tissues 
were greater than in the normal adjacent tissues by comparing the cytosine/thymine 
ratio. The disadvantage of this method was that only a few of the CpG sites in one run 
could be detected which might not represent the whole CpG island.  
The advantage of the Sanger sequencing method was that the methylation 
status of the whole CpG island could be evaluated. The disadvantage was that after 
bisulfite treatment, the converted DNA might contain poly T or poly A. When the poly 
T/A sequences are too long, it would be difficult to sequence by this method. Sanger 
sequencing without cloning only gives information about the average product. To get 
statistically meaningful data commonly cloning and sequencing individual molecules 
are needed. 
Both of the sequencing methods were used for this study as they are 
complementary to each other and the results using one method can be confirmed by 
the other. The results suggest that hypermethylation is not a mechanism of SEL1L 
downregulation. However, in some rare cases, alternate promoters containing CpG 
islands may exist in or around some genes which can also regulate gene expression. 
This possibility can be further studied for the SEL1L gene. 
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Chapter 4 
 
SEL1L and MicroRNA 
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4.1 Introduction 
MiRNAs are endogenous non-coding RNAs ~ 18–24 nucleotides long. 
Generally, miRNAs bind to the 3′ untranslated region (UTR) of their target genes 
through imperfect complementation and repress gene expression either by increasing 
mRNA degradation or by inhibiting translation [88]. Whether the binding of miRNA 
drives mRNA degradation or translational inhibition of the target gene depends on the 
structure of the miRNA–mRNA duplex. Many studies have reported that miRNA may 
repress target gene translation even when it does not affect the mRNA level [89].  
Emerging evidence shows that deregulated miRNAs may play an oncogenic or 
tumor-suppressive role in different kinds of cancers by repressing the expression of 
oncogenes or tumor suppressor genes [90, 91]. In PDAC, it has been reported that 
microRNA-155 inhibits the expression of tumor suppressor gene tumor protein 53-
induced nuclear protein 1 (TP53INP1), and microRNA-21 regulates the expression of 
the tumor suppressor programmed cell death 4 (PDCD4) [92, 93]. Because miRNAs 
can be shed into the serum and be isolated and studied, they may serve as biomarkers 
for early detection and diagnosis of cancers, and for evaluating patients’ prognoses 
[94]. In addition, the functional involvement of these miRNAs in tumorigenesis makes 
them potential therapeutic targets for the treatment of PDAC [95, 96]. 
The 3′ UTR of the SEL1L gene is larger than 4000 bp and thus provides great 
potential to bind miRNAs. Using miRNA microarrays, three studies have investigated 
the genome-wide alterations in miRNA expression found in PDAC [97-99]. There are 
18 miRNAs that displayed upregulation in PDAC in at least two of these studies. In 
this study, I sought to determine whether these aberrantly upregulated miRNAs are 
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responsible for SEL1L downregulation in PDAC using both statistical and functional 
analysis. 
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4.2 Materials and Methods 
 
Materials  
RNA samples from a total of 42 tumor/normal pairs were examined using 
qPCR. Protein samples from 40 out of the 42 pairs have been used for Western 
blotting. MDAPanc3, MDAPanc28, MDAPanc48A and MDAPanc48B cell lines were 
established in our laboratory, all other cell lines used in this study were purchased 
from ATCC. 
 
Extraction of DNA, RNA, and Protein 
Total RNA including miRNA extraction and DNA extraction have been 
previously described in the Methods section in Chapter 1. Protein was isolated from 
the phenol–ethanol supernatant obtained after precipitation of the RNA and DNA. 
Protein concentrations were determined with the bicinchoninic acid (BCA) protein 
assay reagents (Pierce, Rockford, IL). 
  
MiRNAs predicted to target SEL1L 
The microRNA.org resource (miRanda) was searched to identify which of the 
18 aberrantly upregulated miRNAs were predicted to target SEL1L. MiRanda is a 
comprehensive resource for miRNA target predictions that computes the optimal 
sequence complementarity between a mature miRNA and an mRNA using a weighted 
dynamic programming algorithm [100]. From the search, 7 miRNAs were identified 
that potentially target SEL1L: hsa-mir-143, hsa-mir-155, hsa-mir-181a, hsa-mir-181c, 
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hsa-mir-205, hsa-mir-210, and hsa-mir-223. The predicted binding sites and the 
chromosomal locations of these miRNAs are shown in Table 2. 
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qPCR  
Assessment of SEL1L mRNA expression has been described in the Methods 
section in Chapter 2.  The expression levels of the 7 mature miRNAs were examined 
in the DNA Analysis Facility at UTMDACC. The TaqMan MicroRNA Assay kits 
individually targeting the 7 miRNAs (Applied Biosystems) were used for the assays. 
RNA from the matched normal-appearing adjacent tissue was used as a calibrator for 
the tumor. Expression of the miRNAs was normalized to that of U6B small nuclear 
RNA (RNU6B). All of the assays were run in duplicate and an average RQ was 
calculated as final result. Again, a gene was considered to be upregulated if RQ > 2, 
and was considered to be downregulated if RQ < 0.5. 
 
Western blotting 
Thirty micrograms of each of the protein samples were resolved on 10% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then 
proteins were transferred to 0.45 µM nitrocellulose membrane (Bio-Rad Laboratories, 
Hercules, CA). A goat polyclonal antibody to SEL1L (Santa Cruz Biotechnology, 
Santa Cruz, CA) was used at 0.8 µg/mL in tris-phosphate buffered saline (TPBS) with 
5% Blotto (GE Healthcare, Piscataway, NJ). Bovine anti-goat immunoglobulin G-
horseradish peroxidase (IgG-HRP) secondary antibody (Santa Cruz Biotechnology) 
was used at a dilution of 1:5000. TPBS with 0.2% Tween20 (Sigma-Aldrich, St. 
Louis, MO) was used as washing buffer to reduce the high background of non-specific 
blotting when using a goat antibody. The membrane was washed 3 times for 15 
minutes following antibody incubation. The GAPDH antibody (Abcam, Cambridge, 
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MA) was used as a loading control at a concentration of 0.4 µg/mL. Goat anti-rabbit 
IgG-HRP (Santa Cruz Biotechnology) was used as a secondary antibody to GAPDH at 
a dilution of 1:5000. The membrane was washed in TPBS with 0.05% Tween20 3 
times for 10 minutes following the antibody incubation. 
Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare) 
were used to detect the signals. The intensity of the bands on Western blots was 
measured with Quantity One version 4.6.1 analysis software (Bio-Rad Laboratories). 
Desired bands from two exposure times (20 seconds and 1 minute) were quantified, 
and their average intensities were calculated. The RQ of SEL1L protein expression in 
the tumor was normalized to that of GAPDH and compared with that of the matched 
normal-appearing adjacent tissue.   
 
Statistical analysis  
The Fisher’s exact test was used to evaluate the association between the 
expression levels of SEL1L mRNA and the miRNAs. The Kruskal–Wallis test was 
used to evaluate expression differences between the groups with 0, 1, 2, or 3 
upregulated miRNAs. Pearson’s correlation coefficient was used to measure the 
correlation between SEL1L mRNA expression and SEL1L protein expression in 
PDAC tumors. All tests of statistical significance were 2-sided. P < 0.05 was 
considered statistically significant. All statistical analyses were performed using Stata 
version 10.1 software (Stata, College Station, TX).        
 
Cell culture  
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The PDAC cells, including Panc1, BxPC3, MiaPaCa2, ASPC1, Capan1, 
Capan2, PL3, PL18, MDAPanc3, MDAPanc28, MDAPanc48A and MDAPanc48B, as 
well as Human Embryonic Kidney (HEK) 293T cells were maintained at 37°C and 
5% CO2 in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) 
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) 
(Gemini Bio-Products, West Sacramento, CA) and 1% penicillin/streptomycin 
(Mediatech). The hTERT-HPNE cells were cultured in 75% DMEM without glucose 
(Mediatech), 25% Medium M3 Base (Incell Corporation, San Antonio, TX) 
supplemented with 10 ng/ml human recombinant EGF (Sigma-Aldrich), 5.5 mM D-
glucose (Mediatech), 5% FBS and 0.75% puromycin (Mediatech). 
  
Luciferase assay 
The pMIR-REPORT miRNA Expression Reporter Vector System (Applied 
Biosystems) was used to determine whether the miRNAs bind to the predicted binding 
sites and regulate reporter expression. The pMIR-REPORT Luciferase Reporter 
Vector may produce high-level expression of firefly luciferase under the control of a 
mammalian promoter/terminator system. The miRNA target cloning region is located 
downstream, i.e. 3’ UTR, of the luciferase sequence. The predicted SEL1L–miRNA 
binding sites and more than 100 bp of flanking sequence at both the 5’ and 3’ ends 
were inserted into the cloning region. Because the putative binding sites for hsa-mir-
155 and hsa-mir-223 are very close to each other, a construct containing the putative 
binding sites for both of the miRNAs was established (Figure 10). The 100 bp 
flanking sequences help to ensure that the secondary structure of the binding sites will 
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not be interrupted and thus better represent the in vivo condition. A second vector, 
pMIR-REPORT Beta-galactosidase (ß-gal) Reporter Vector, was used for 
normalization of transfection efficiency. A relative expression of the firefly luciferase 
was calculated by comparing that to the expression of ß-gal signal. For example, the 
average reading of the firefly luciferase signal in a sample was 6288437 and the 
average reading of the ß-gal signal in this sample was 47494, so the relative 
expression of the firefly luciferase was 6288437 / 47494 = 132.40.  
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A. 
CTGAGAAACTCTTACCAGTCCACATGCAATTAGACATATTCAGCATATTTGTTATTTTAAAAGGGAGGG
TTGGGAGGTTTCTTATTGGTGATTGTCACACGGTATACCATACTCCTCTCCTTCAAAGAATGAAAGGCC
TTGTTAAGGAGTTTTTTGTGAGCTTTACTTCTTTGGAATGGAATATACTTATGCAAAACCTTGTGAACT
GACTCCTTGCACTAACGCGAGTTTGCCCCACCTACTCTGTAATTTGCTTGTTTGTTTTGAATATACAGA
GCCTTGATCCAGAAGCCAGAGGATGGACTAAGTGGGAGAAATTAGAAAACAAAACGAACTCTGGTTGGG
GTACTACGATCACAGACACAGACATACTTTTCCTAAAGTTGAAGCATTTGTTCCCAGGATTTATTTTAC
TTTGCATTTCTTTTTGCACAAAGAACACATCACCTTCCTGAATTCTTTAAATATGAAATATCATTGCCA
GGGTATGGCTTACAGTGACTACTATTATAATACTAAAACTCAGAGAATCAAAGATGGATTAAACTCAGT
GGTTGATGAAAGCCAAAACCTGTTTGTACTGTTCTATACTATTCAGGTATCTTTTTATTTCTGATAGTT
TTATATTATAATAGAAAGCCAGCCACTGCTTAGCTATCATAGTCACCATTTTCTCACTGTTAACATTAG
GAAAATCAAGGCTACTATGCTTCAGGATTGTCTGGTTAAATAGTATGGGAAAAAAACTGAAGAGTTTCA
CATAATTACACACGTGAAATAATTAAAGCTT 
B.  
 
 
 
 
 
 
 
Figure 10. pMIR-REPORT Luciferase Reporter construct containing predicted 
binding sites of SEL1L to hsa-mir-155 and hsa-mir-223. A. Sequence that was 
inserted into the vector. Yellow highlight: hsa-mir-223 binding site; Red highlight: 
hsa-mir-155 binding site. B. Schematic diagram of the construct. 
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MDAPanc3 cells, PL18 cells or BxPC2 cells were plated in 6-well plates and 
reached a cell confluency of 50%-60% at the time of transfection. In each well, a 
mixture of 1.5 ug of Luciferase Reporter plasmid DNA (with or without the binding 
sites) and 0.15 ug of ß-gal Reporter plasmid DNA was transfected into the cells with 5 
ul of  Lipofectamine LTX (Invitrogen) and 1.65 ul of PLUS reagent (Invitrogen). Cells 
were washed with PBS twice and collected after 24 hours and 48 hours. Firefly 
luciferase activity and ß-gal activity were determined by using the Dual-Light 
Luciferase and ß-Galactosidase Reporter Gene Assay System (Applied Biosystems) 
according to the manufacturer’s instructions. A 20/20n Single Tube Luminometer 
(Turner Biosystems, Sunnyvale, CA) was used for the measurements. All of the 
transfections were performed in triplicate and the average activities were calculated. 
Then the firefly luciferase activities were normalized to ß-gal activity. 
293T cells were plated in 24-well plates and transfected at a cell confluency of 
80-90%. The cells were transfected with 200 ng of Luciferase Reporter plasmid DNA 
(with or without the binding sites), 5ng of ß-gal Reporter plasmid DNA, and 5 pmol of 
miRNA precursor or negative control (final concentration 25 nM) using 2 ul of 
Lipofectamine2000 (Invitrogen). The miRNA precursors and negative control (miR-
control) were purchased from Ambion/Applied Biosystems. The miRNA precursors 
are synthetic, chemically modified double-stranded RNA molecules that mimic 
endogenous mature miRNAs. The negative control is similar to the miRNA precursor 
with a random sequence that has been validated not to produce identifiable effects on 
known miRNA function. Cells were harvested after 48 hours of the co-transfection. 
Firefly luciferase activity and ß-gal activity were assessed as described in the last 
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paragraph. 
 
MiRNA inhibition and overexpression 
Chemically modified antisense oligoribonucleotides, termed “antagomirs”, 
were used in this study to inhibit hsa-mir-155 and hsa-mir-223. Antagomirs have been 
reported to specifically, efficiently reduce the expression of corresponding miRNAs 
[101]. The antagomir against hsa-mir-155 is: 5’-mA*mC*mCmCmCmUmAmUmC-
mAmCmGmAmUmUmAmG-mCmAmU*mU*mA*mA*/Chol-3’. The antagomir 
against hsa-mir-223 is: 5’-mU*mG*mGmGmGmUmAmUmUmUmGmAmCmAmA 
mAmCmUmG*mA*mC*mA*/Chol-3’. The negative control for the antagomirs is: 5’-
mA*mA*mGmUmGmGmAmUmAmUmUmGmUmUmGmCmCmA*mU*mC*mA*/
Chol-3’. The lower case “m” represents 2’-O-methyl-modification; the asterisk 
(*) represents a phosphor-rothioate linkage; and “Chol” represents cholesterol linked 
through a hydroxyprolinol linkage. The negative control is a random sequence that has 
been validated by Ambion not to inhibit any known miRNA function. These 
antagomirs were synthesized and then purified by high-performance liquid 
chromatography (Integrated DNA Technologies, Coralville, IA). 
BxPC3, PL18 or Capan2 cells were plated in 6-well plates and reached a cell 
confluency of 50%-60% at the time of transfection. In each well, 200 pmol of the 
antagomir or negative control (final concentration 200 nM) was transfected into the 
cells with 2 ul of Oligofectamine (Invitrogen). For PL18 cells, after 24 hours of 
transfection, a double knockdown was performed by transfecting the same amount of 
hsa-mir-155 antagomir into the cells again.  
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Ambion miRNA precursors and negative control were used for the 
overexpression study of the miRNAs of interest. MDAPanc3 or Miapaca2 cells were 
plated on 6-well plates and reached a cell confluency of 50%-60% at the time of 
transfection. In each well, 30 pmol of miRNA precursor or negative control (final 
concentration 30 nM) was transfected into the cells using 2 ul of Oligofectamine 
(Invitrogen).  
The cells mentioned above were washed with PBS twice and collected after 24 
hours, 48 hours and 72 hours. Then total RNA and protein were extracted for qPCR 
and Western blotting as described previously. Proteins also were extracted by lysing 
the cells in Radio-Immunoprecipitation Assay (RIPA) buffer (Sigma-Aldrich).  
 
Reverse phase protein assay (RPPA) 
The cell lysates were denatured with 1% SDS (with beta-mercaptoethanol) and 
diluted in five 2-fold serial dilutions in lysis buffer containing 1% SDS. Serial diluted 
lysates were arrayed on nitrocellulose-coated slides (Grace Bio-lab, Bend, OR) using 
an Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA). Each slide was probed 
with validated primary antibodies plus biotin-conjugated secondary antibodies. A total 
of 172 antibodies including 23 replicated antibodies were included in the data set 
(SEL1L antibody was not available for this experiment). All the proteins assessed are 
related to cancer pathogenesis. Each array included spots corresponding to positive 
and negative controls prepared from mixed cell lysates or dilution buffer, respectively. 
The signal obtained was amplified using a Dako Cytomation–catalyzed system (Dako, 
Carpinteria, CA) and visualized by diaminobenzidine (DAB) colorimetric reaction. 
  
58 
The slides were scanned, analyzed, and quantified using a customized-software 
Microvigene (VigeneTech Inc., Carlisle, MA) to generate spot intensity. Protein levels 
for each sample were determined by interpolation of each dilution curve into a logistic 
model, Supercurve Fitting, developed by the Department of Bioinformatics and 
Computational Biology at UTMDACC [102]. This model fits a single curve using all 
the dilution series on a slide with the signal intensity as the response variable and the 
dilution steps as independent variables. The protein concentrations of each set of slides 
were then normalized by median polish, which was corrected across samples by the 
linear expression values using the median expression levels of all antibody 
experiments to calculate a loading correction factor for each sample. A relative protein 
expression level was calculated by comparing the normalized linear value in the 
sample transfected with miRNA precursor to that in the sample transfected with 
negative control at the same time point. A protein was considered to be upregulated if 
RQ > 1.500, and to be downregulated if RQ < 0.667. 
  
Ingenuity pathways analysis (IPA) 
The “Core Analysis” function in IPA (Ingenuity System Inc, Redwood City, 
CA) was used to interpret the RPPA data for pathways and networks involved [103]. 
Molecules from the data set that displayed expression variation and were contained in 
the Ingenuity Knowledge Base were analyzed. The significance of the association 
between the data set and the canonical pathway was measured by Fisher’s exact test to 
calculate a P‐value. These molecules were also overlaid onto a global molecular 
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network developed from information in the Ingenuity Knowledge Base, and networks 
were then algorithmically generated based on their connectivity. 
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4.3 Results 
 
Expression levels of hsa-mir-143, hsa-mir-155, and hsa-mir-223 are inversely 
correlated with SEL1L mRNA expression in PDAC tumors  
Results from quantitative RT-PCR indicated that SEL1L mRNA was 
downregulated in 55% of the PDAC tumors, whereas the 7 miRNAs were upregulated 
in the following percentages of the PDAC tumors: hsa-mir-155, 52%; hsa-mir-205, 
45%; hsa-mir-210, 45%; hsa-mir-181c, 40%; hsa-mir-143, 38%; hsa-mir-181a, 35%; 
and hsa-mir-223, 33% (Figure 11). 
The RQs of the expression of SEL1L mRNA and the 7 miRNAs were initially 
assessed in 20 pairs of PDAC tumors and normal-appearing adjacent tissues by qPCR. 
The preliminary data showed that only levels of hsa-mir-143, hsa-mir-155, and hsa-
mir-223 correlated significantly with SEL1L mRNA expression. Subsequent analyses 
of an additional 22 pairs of samples for these 3 miRNAs corroborated these findings, 
and the combined data from a total of 42 samples pairs are presented in Table 3.  
The downregulation of SEL1L mRNA was found to be significantly associated 
with the upregulation of hsa-mir-143, hsa-mir-155, and hsa-mir-223 as evaluated 
using Fisher’s exact test (P < 0.0001, P < 0.0001, and P = 0.002, respectively). As 
shown in Table 3, of the samples in which these miRNAs were upregulated, 14 (88%) 
out of 16, 18 (82%) out of 22, and 12 (86%) out of 14, respectively, showed SEL1L 
mRNA downregulation. Furthermore, of the 23 tumor samples in which SEL1L 
mRNA was downregulated, 20 (87%) displayed upregulation of at least 1 of these 3 
miRNAs. The other 4 miRNAs (hsa-mir-181a, hsa-mir-181c, hsa-mir-205, and hsa-
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mir-210) did not show a significant correlation with SEL1L mRNA expression (P = 
0.749, P = 0.763, P = 0.654, and P = 0.469, respectively).  
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Figure 11. Percentage of the deregulation of SEL1L mRNA and 7 miRNAs in 
PDAC tumors.  
Blue columns indicate gene upregulation. Pink columns indicate gene downregulation. 
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Inverse correlation between miRNA expression and SEL1L expression 
As shown in Figure 12, the samples were divided into 4 groups on the basis of 
the number (0, 1, 2, or 3) of upregulated miRNAs in each sample. Because only hsa-
mir-143, hsa-mir-155, and hsa-mir-223 showed correlations with SEL1L mRNA 
expression, this study was focused on the upregulation of these 3 miRNAs. The RQs 
of SEL1L mRNA expression in the tumors were compared for the groups.  It was 
determined that as the number of overexpressed miRNAs increased, the median RQ of 
SEL1L mRNA expression decreased. The RQs of SEL1L mRNA expression among 
the four groups were significantly different (P = 0.004), and the trend of an increasing 
number of upregulated miRNAs corresponding to decreasing expression of SEL1L 
mRNA was also significant (Ptrend = 0.001).  
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Figure 12. RQ of SEL1L mRNA expression in PDAC tumors plotted against the 
number of upregulated miRNAs.  
Each horizontal line of pluses (+) and the number next to it represent the median fold 
change in SEL1L mRNA expression for that number of upregulated miRNAs. 
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The expression levels of hsa-mir-143, hsa-mir-155, and hsa-mir-223 are 
significantly associated with each other 
The pairwise association was also evaluated between hsa-mir-143, hsa-mir-
155, and hsa-mir-223 using Fisher’s exact test (Table 4). Of the 42 tumor samples, 26 
(62%) showed the same trend of expression between hsa-mir-143 and hsa-mir-155, 25 
(60%) between hsa-mir-143 and hsa-mir-223, and 24 (57%) between hsa-mir-155 and 
hsa-mir-223. They were all significantly associated with each other (P = 0.015, P = 
0.003, and P = 0.010, respectively). 
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SEL1L protein expression correlates significantly with SEL1L mRNA expression  
Because miRNAs may block target gene translation directly [88], SEL1L 
protein expression levels were assessed to determine whether the protein levels 
parallel the mRNA levels or whether the proportion of downregulation in PDAC 
tumors is greater at the protein level than at the mRNA level. The results are shown in 
Table 5. For both SEL1L mRNA and SEL1L protein, again the RQs of 2 and 0.5 were 
used as the cutoff values for considering a gene to be up- and downregulated. In those 
samples where the mRNA and the protein showed different trends of expression, 
Western blotting was repeated and the average RQ was calculated as the final result. 
Of the 40 PDAC tumor samples listed in Table 5, it was determined that unlike 
SEL1L mRNA that was downregulated in 21 (53%) of the PDAC tumors, SEL1L 
protein was downregulated in only 16 (38%). In these 16 tumors, SEL1L mRNA was 
always downregulated. SEL1L mRNA and SEL1L protein displayed the same trends 
of expression (both up, both down, or both normal) in 32 (80%) of the 40 cases. The 
representative results of Western blotting are shown in Figure 13A. Pearson’s 
correlation test showed that the RQ of SEL1L protein expression varied directly with 
the RQ of SEL1L mRNA expression and was statistically significant (Figure 13B).  
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A.  
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 13. SEL1L protein expression and comparison to its mRNA expression. 
A. Representative results of Western blotting (cropped image). Sample numbers 
follow table 5. T: PDAC tumor sample; N: normal adjacent tissue. B. Pearson's 
correlation scatter plot of SEL1L mRNA and protein relative fold change in 40 
PDACs. The plot shows linear regression with R2 = 0.605 (r = 0.778).  
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Expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 in pancreatic cancer cell 
lines were determined by qPCR 
The hTERT-HPNE cell line was used as a “normal” control. This immortalized 
cell line was derived from normal ducts of the human pancreas and is the closest thing 
to normal human pancreas in terms of cell lines. The hTERT-HPNE cells have been 
found to have the ability to differentiate into pancreatic ductal cells [104].  
The expression levels of hsa-mir-143, hsa-mir-155 and hsa-mir-223 were 
assessed in 12 pancreatic cancer cell lines and in the hTERT-HPNE cell line by qPCR. 
The RQs of these 3 miRNAs in the PDAC cell lines were then compared to the 
corresponding RQ in the hTERT-HPNE cell line. As shown in Figure 14, for hsa-mir-
143, all the PDAC cell lines displayed relatively low levels of expression; for hsa-mir-
155, the PDAC cell lines showed variable expression levels; for hsa-mir-223, only 
BxPC3 displayed a high level of expression and all of the other11 PDAC cell lines 
showed relatively low levels of expression.  
The low expression level of hsa-mir-143 in the 12 PDAC cell lines indicates 
that these cell lines cannot serve as an ideal model for hsa-mir-143 functional analysis. 
Therefore, the functional analysis was focused on the other 2 miRNAs, hsa-mir-155 
and hsa-mir-223.  
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Figure 14. Expression of 3 miRNAs in PDAC cell lines. 
Each column represents the relative expression level of the 3 miRNAs in the 12 PDAC 
cell lines. The expression level in the hTERT-HPNE cell line was set as 1 fold. Names 
of the miRNAs are labeled at the right, and names of the cell lines are labeled at the 
bottom. 
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pMIR-REPORT Luciferase Reporter construct vector showed decreased reporter 
expression in PL18 cell line 
The pMIR-REPORT Luciferase Reporter Construct with putative hsa-mir-155 
and hsa-mir-223 binding sites was transfected into two PDAC cell lines, PL18 and 
MDAPanc3, as described in the Methods. From the results in Figure 14, it was 
determined that PL18 has a relatively high expression level of hsa-mir-155; and 
MDAPanc3 has a very low expression level. Both of these 2 cell lines showed a low 
level of hsa-mir-223 expression. In the PL18 cells transfected with the construct 
vector, a significant decrease was found in firefly luciferase expression in comparison 
to the cells transfected with empty vector. However, for the MDAPanc3 cell line, there 
was no significant difference found in luciferase expression between the cells 
transfected with the construct vector and with the empty vector. These results are 
shown in Figure 15. 
BxPC3 cells were also transfected with pMIR-REPORT Luciferase Reporter 
Vectors using the same protocol. It was determined that BxPC3 has a high expression 
level of both hsa-mir-155 and hsa-mir-223. However, there was no significant 
difference observed between the results of transfection of the construct vector and of 
the empty vector. It was noticed that the luciferase signal in BxPC3 cells was more 
than 100 times lower than that in other cells indicating low transfection efficiency in 
this cell line (data not shown). Therefore, the data obtained from experiments using 
BxPC3 cells may not be reliable. 
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Figure 15. Luciferase assay of pMIR-REPORT Luciferase Reporter Vector 
transfection in 2 PDAC cell lines. 
Empty: cells transfected with the vector without an insert. Construct: cells transfected 
with the vector containing the putative binding sites. The asterisk (*) indicates a 
significant difference between the results from empty vector transfection and the 
construct transfection (t-test, P < 0.05). Error bars indicate standard deviation of the 
relative luciferase expression (n = 3). 
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pMIR-REPORT Luciferase Reporter construct vector did not show difference in 
reporter expression in 293T cells co-transfected with the miRNA precursors  
The 293T cell line is a derivative of HEK 293 cell lines containing the SV40 
Large T-antigen. This cell line is easily transfected with plasmids containing the SV40 
origin of replication. Gironella et al. used this cell line to co-transfect a reporter 
construct vector and hsa-mir-155 precusor [92]. Therefore, this cell line was chosen 
for the co-transfection experiment. However, there was no significant difference found 
in luciferase expression between the cells transfected with the negative control and 
with the miRNA precursors. Luciferase assay results from co-transfection of either the 
empty vector or the construct vector are shown in Figure 16. 
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Figure 16. Luciferase assay of pMIR-REPORT Luciferase Reporter Vector co-
transfection with miRNA precursors in 293T cell line. 
Empty: cells transfected with the vector without an insert. Construct: cells transfected 
with the vector containing the putative binding sites. The cells were co-transfected 
with either the negative control, or 1 or 2 miRNA precursors. Error bars indicate 
standard deviation of the relative luciferase expression (n = 3). 
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SEL1L expression did not change after transfection of antagomirs 
Because the BxPC3 cell line has very high expression levels of both hsa-mir-
155 and hsa-mir-223, the antagomirs were transfected into this cell line to evaluate 
their effect on the expression of either one or two of the miRNAs. Real-time qPCR 
results indicated that 24 hours and 48 hours after transfection of the hsa-mir-155 
antagomir, the expression of hsa-mir-155 was more than 2 fold downregulated. 
However, in the cells transfected with the hsa-mir-223 antagomir, there were no 
obvious changes in the expression of hsa-mir-223. Both qPCR and Western blotting 
did not reveal substantial changes in the expression of SEL1L at the mRNA level or 
protein level, including in the samples where hsa-mir-155 was downregulated. Results 
are shown in Figure 17. 
 The Capan2 cell line showed a moderate expression level of both hsa-mir-155 
and hsa-mir-223. The antigomirs were transfected into this cell lines using the exact 
same protocol as for BxPC3. Similar results were obtained as seen for the BxPC3 cell 
line and the expression of SEL1L did not significantly change after the transfection of 
the antagomir(s). The results are shown in Figure 18. 
The hsa-mir 155 antagomir was also been transfected into PL18 cells. This 
time, a double knockdown was performed as described in the Methods section. qPCR 
results indicated that hsa-mir-155 was further downregulated 48 hours after the second 
transfection (RQ = 0.18). However, there were still no substantial changes observed in 
the expression of SEL1L at either the mRNA level or protein level. The results are 
shown in Figure 19.  
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A.  
 
B.  
 
 
 
                   1      2       3       4      5       6      7      8 
 
Figure 17. Expression of SEL1L after transfection of antagomirs against hsa-mir-
155 and hsa-mir-223 in BxPC3 cells. 
A. Relative quantities of hsa-mir-155, hsa-mir-223 and SEL1L mRNA determined by 
qPCR. Anta, samples transfected with antagomir(s); NC, samples transfected with 
negative control to antigomir; hr, hours after transfection. Sample numbers are noted 
at the left of each name. Red numbers indicate downregulation. B. SEL1L protein 
expression determined by Western blotting. Sample numbers are the same as those in 
panel A.  
SEL1L 
GAPDH 
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A. 
 
 
 
 
 
B.  
 
 
 
                 1         2        3       4         5        6        7         8 
 
Figure 18. Expression of SEL1L after transfection of antagomirs against hsa-mir-
155 and hsa-mir-223 in Capan2 cells. 
A. Relative quantities of SEL1L mRNA determined by qPCR. Anta, samples 
transfected with antagomir(s); NC, samples transfected with negative control to 
antigomir; hr, hours after transfection. Sample numbers are noted at the left of each 
name. B. SEL1L protein expression determined by Western blotting. Sample numbers 
are the same as those in panel A.  
 
 
SEL1L 
GAPDH 
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A.  
 
 
B.                       
 
 
             1      2      3       4      5       6       7        8       9     10 
 
Figure 19. Expression of SEL1L after transfection of antagomir against hsa-mir-
155 in PL18 cells. 
A. Relative quantities of SEL1L mRNA determined by qPCR. Anta, samples 
transfected with antagomir; NC, samples transfected with negative control to 
antigomir; hr, hours after transfection. Double, transfection twice of the antagomir and 
the time points were taken after the second transfection. Sample numbers are noted at 
the left of each name. Red numbers indicate downregulation. B. SEL1L protein 
expression determined by Western blotting. Sample numbers are the same as those in 
panel A.  
SEL1L 
GAPDH 
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SEL1L protein expression was downregulated after transfection of hsa-mir-155 
precursor in MDAPanc3 cells 
 Both MDAPanc3 and Miapaca2 cells have a very low expression level of hsa-
mir-155 and hsa-mir-223. The expression levels of these 2 miRNAs were assessed 
after the transfection of the miRNA precursors using qPCR. As shown in Figure 20, 
the expression level of the miRNA markedly increased after transfection of the 
precursor when compared to the negative control (> 1000 folds). The endogenous 
control RNU6B exhibited similar expression levels for all the samples indicating that 
there was a similar amount of the initial cDNA. 
 The qPCR results in Figure 21A revealed that the expression level of SEL1L 
mRNA did not change even though hsa-mir-155 and hsa-mir-223 were overexpressed. 
However, from the Western blotting results in Figure 21B and 21C, it was determined 
that when hsa-mir-155 was overexpressed in MDAPanc3 cells the SEL1L protein 
displayed decreased expression level. When hsa-mir-223 alone was overexpressed, no 
significant changes were observed in SEL1L protein expression. When the precursors 
were transfected into Miapaca2 cells, there were no detectable changes in SEL1L 
expression levels (Figure 22).  
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Figure 20. Representative qPCR amplification plot of miRNA expression after 
precursor transfection. 
An increase in fluorescence indicates the detection of accumulated PCR product. 
Quantitation of the amount of target is measured by cycle number. The higher the 
initial amount of target cDNA, the sooner accumulated product is detected in the PCR 
process, and the lower the cycle number. Curve 1, detection of miRNA in sample 
transfected with miRNA precursor; curve 2, detection of miRNA in sample transfected 
with negative control to the precursor; curve 3, detection of RNU6B in both samples. 
All measurements were duplicated. 
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Figure 21. Expression of SEL1L after transfection of hsa-mir-155 and hsa-mir-
223 precursors in MDAPanc3 cells. 
A. Relative quantities of SEL1L mRNA determined by qPCR. Pre, samples transfected 
with miRNA precursor; NC, samples transfected with negative control to miRNA 
precursors; hr, hours after transfection. B, C. SEL1L protein expression determined by 
Western blotting.  
SEL1L 
GAPDH 
SEL1L 
GAPDH 
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Figure 22. Expression of SEL1L after transfection of hsa-mir-155 and hsa-mir-
223 precursors in Miapaca2 cells. 
A. Relative quantities of SEL1L mRNA determined by qPCR. Pre, samples transfected 
with miRNA precursor; NC, samples transfected with negative control to miRNA 
precursors; hr, hours after transfection. B, C. SEL1L protein expression determined by 
Western blotting.  
SEL1L 
GAPDH 
SEL1L 
GAPDH 
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Sixteen proteins showed expression level changes after transfection of mir-155 
precursor in MDAPanc3 cells 
Reverse phase protein assay (RPPA) was applied to measure the transient 
response of the MDAPanc3 PDAC cells to the overexpression of hsa-mir-155. 
MDAPanc3 cells were transfected with hsa-mir-155 precursor or negative control and 
were collected after 48 hours and 72 hours, and then analyzed by RPPA. The 
expression levels of 12 proteins assessed were found to be downregulated and 4 were 
upregulated. Among these, 6 phosphorylation state-specific antibodies assessed 
phosphorylation at specific sites of target proteins.  The relative quantities of these 
proteins are listed in Table 6A. All other proteins that were analyzed by RPPA did not 
show expression alterations and are listed in Table 6B. Through a search of the 
microRNA.org resource, it was determined that only the kinase insert domain receptor 
(KDR), epidermal growth factor receptor (EGFR), and v-rel reticuloendotheliosis viral 
oncogene homolog A (RELA) genes in Table 6Ahad potential binding sites to hsa-mir-
155, therefore only these three genes would be expected to be downregulated by the 
overexpression of hsa-mir-155. This indicated that most of the protein expression 
changes were possibly induced through cellular networks instead of direct regulation 
by hsa-mir-155.  
The data in Table 6A along with SEL1L protein expression data assessed by 
Western blotting were then uploaded to the IPA program. Through the use of IPA, 5 
canonical pathways were found to be significantly associated with this data set, 
including pancreatic adenocarcinoma signaling and PTEN signaling (Table 7A). The 
three top involved networks were generated through the use of IPA and are 
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summarized in Table 7B. SEL1L was shown to be associated with a network which 
functions in cell death, gene expression and organismal development. Another 
downregulated protein, ERCC1, was shown to be in the same network. 
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4.4 Discussion 
In this study, aberrantly upregulated miRNAs in PDAC were studied to 
determine if they are involved in the downregulation of SEL1L. The miRNA target 
prediction tools helped in the selection of the miRNAs that potentially target SEL1L. 
However, the pairing match between a miRNA and a gene is not the only factor that 
influences the ability of a miRNA to bind and repress a target gene. Other 
characteristics, such as the binding position in the UTR, the flanking sequences, and 
mRNA secondary structures, are also important factors in predicting whether a 
miRNA is likely to repress the expression of a target gene [105]. Therefore, statistical 
methods were used to assess the probability that these 7 miRNAs target and repress 
SEL1L gene expression.  
A significant correlation was observed between the expression of SEL1L 
mRNA and 3 of the 7 miRNAs that had potential binding sites for SEL1L. The 
expression of these 3 miRNAs (hsa-mir-143, hsa-mir-155, and hsa-mir-223) was 
found to be inversely associated with SEL1L mRNA expression in a high proportion 
of PDAC tumors, indicating that these miRNAs possibly repress the expression of 
SEL1L in some of the PDAC tumors. 
Other investigators have shown that multiple coexpressed miRNAs can target a 
single mRNA and work together to repress the gene expression [106-108]. Velu et al. 
have recently demonstrated that two miRNAs, miR-21 and miR-196b, work 
synergistically in Lin- bone marrow cells to increase the blocking of granulopoiesis 
[105]. Similarly, the data presented here demonstrated that the overexpression of an 
increasing number of functional miRNAs in PDAC is associated with an increasing 
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repression of SEL1L mRNA expression. This statistical result suggests that the 3 
miRNAs may work cooperatively to regulate SEL1L expression.  
Although hsa-mir-143, hsa-mir-155 and hsa-mir-223 are located on different 
chromosomes, a significant pairwise correlation between their expression profiles was 
observed. These results suggest that the deregulation of the 3 miRNAs may be caused 
by the same mechanism, such as mutant transcription factors that can bind to (or fail to 
bind to) the putative regulatory motifs that all 3 miRNA genes have in common [109]. 
Discovering and understanding the common regulatory mechanisms involved could 
provide new insight into the molecular mechanisms underlying pancreatic 
tumorigenesis.    
A recent publication in Nature demonstrated that for miRNA regulatory 
interactions, more than 84% of the lowered protein production was associated with 
decreased mRNA levels [110]. The results indicated that destabilization of target 
mRNAs is the predominant impact of miRNAs on gene expression. In this study, the 
direct correlation between the expression of SEL1L mRNA and SEL1L protein also 
suggests that mRNA abundance is a key modulator for SEL1L protein expression in 
PDAC. For the small proportion of samples in which mRNA and protein expression 
were not correlated (20%), other mechanisms may be involved in regulation of SEL1L 
protein expression. Because many mechanisms affect protein levels at both the 
translational and the post-translational level, the disagreement in this small proportion 
of samples is not surprising [111].  
Correlation between two variables does not imply that one directly causes the 
other, but it suggests a possible avenue warranting further investigation. In this study, 
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the statistical analysis results provided the rationale for conducting further in vivo 
functional analysis to explore the role of specific miRNAs in the regulation of SEL1L 
expression. Luciferease reporter assays, miRNA inhibition and overexpression 
experiments were performed to determine the relationship between SEL1L expression 
and the miRNAs from different aspects. Luciferase reporter assays are a method to 
determine if a miRNA truly binds to a predicted binding site in a gene. Through either 
miRNA inhibition or overexpression, it can be determined whether a miRNA causes a 
change in expression levels of a target gene.  
It is hypothesized that in a cell line with high expression level of the miRNA, 
the reporter expression of vector containing the binding site would be repressed. In 
PL18 cells which have a relatively high expression level of hsa-mir-155, a significant 
decrease in luciferase expression was observed when comparing the experimental 
vector transfection to the results of empty vector transfection. There was no such 
decrease observed in MDAPanc3 cells which have a relatively low expression level of 
hsa-mir-155. These results suggest that hsa-mir-155 does bind to the predicted binding 
site in SEL1L gene. However, the possibility that this result reflected a difference 
between different cell lines cannot be ruled out.  
Although BxPC3 has a high expression level of both hsa-mir-155 and hsa-mir-
223, a decrease in luciferase expression was not detected when the cells were 
transfected with the experimental vector. This assay did not exhibit the expected result 
probably because of the low transfection efficiency in this cell line. 
The cotransfection of luciferase vectors and miRNA precursors in 293T cells 
also did not show the expected results. One explanation for this result is that hsa-mir-
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155 and hsa-mir-223 do not bind to the predicted binding sites. However, there are 
several possible reasons that may have caused a failure of this experiment. First, the 
miRNA precursors in this study do not contain a SV40 origin of replication; therefore, 
high transfection efficiency of the precusors would not be guaranteed, and it is 
possible that the plasmid and a precursor molecule were not transfected into the same 
cell. Second, after transfection a high rate of cell death was observed. The dead cells 
were removed after the PBS wash. The surviving cells examined by the luciferase 
assay may not be good representatives for the co-transfection. 
For the miRNA knockdown experiments, it is hypothesized that inhibiting hsa-
mir-155 and hsa-mir-223 would restore the expression of endogenous SEL1L. The 
qPCR results revealed that hsa-mir-155 was successfully downregulated by the 
antagomir, but the inhibition of hsa-mir-223 did not work for some unknown reason.  
A significant increase in SEL1L expression was not detected at either the 
mRNA level or the protein level in the 3 PDAC cell lines, even though hsa-mir-155 
was inhibited. Maybe hsa-mir-155 is not a modulator of SEL1L and this is the 
simplest explanation for these results. However, there are some other possibilities that 
should also be considered: (1) there is a delay of SEL1L expression change in 
response to the miRNA downregulation, and transient transfection may not reflect the 
delayed response; (2) the 2 to 4-fold reduction of hsa-mir-155 is not sufficient to cause 
a detectable change in SEL1L expression in these experiments; i.e. SEL1L expression 
might have been upregulated but it was not significant enough to be detected; (3) none 
of the 3 cell lines used in this study showed low expression of SEL1L and therefore, 
they may not serve as ideal models to use for examining regulation of SEL1L gene 
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expression. Another possibility is that more than one miRNA is required and this was 
not achieved under these experimental conditions. 
When either hsa-mir-155 or hsa-mir-223 was overexpressed, it was 
hypothesized that the SEL1L gene would be downregulated. A decrease in expression 
of SEL1L protein was observed when the precursor of hsa-mir-155 was transfected in 
MDAPanc3 cells, either alone or with hsa-mir-223. When the precursor of hsa-mir-
223 was transfected alone, a detectable downmodulation of SEL1L was not observed 
in either cell line. These results provided evidence that hsa-mir-155 is a suppressor of 
SEL1L, and hsa-mir-223 is not.  
Unlike in PDAC tumors, in the cells where SEL1L protein expression was 
decreased there was no corresponding mRNA decrease. Larsson et al. found that 
transcripts with high turnover rates are less affected by miRNA overexpression after 
transfection [112]. This may be the explanation for the results that SEL1L mRNA 
perhaps has a high turnover rate and the expression level of the mRNA was not 
significantly affected by the transient transfection of hsa-mir-155.  
MDAPanc3 cell line was established in my adviser (Dr. Frazier)’s laboratory, 
from a liver metastasis of PDAC [113], whereas Miapaca2 was derived from a grade 
G3 primary PDAC tumor [114]. Using Spectral Karyotyping, Sirivatanauksorn et al 
showed that these two cell lines had different cytogenetic aberrations [115]. Because 
of the different histological and genetic background, it is not a surprise that the results 
from these two cell lines are different. The interaction between hsa-mir-155 and 
SEL1L might be interrupted in Miapaca2 cells by unknown factors not found in 
MDAPanc3. Another possibility is that the interaction reflects an indirect interaction 
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in which the overexpressed hsa-mir-155 regulated SEL1L expression through certain 
signaling pathways in MDAPanc3 cells, and these pathways might be disrupted in 
Miapaca2 cells.  
In conclusion, the functional analysis revealed that in the tested PDAC cell 
lines hsa-mir-223 did not act as a suppressor of SEL1L; hsa-mir-155 acted as a 
suppressor of SEL1L but only under some cellular environments, which could be the 
specific genetic background of the cell lines. 
Hsa-miR-155 has been reported to be involved in various biological processes, 
such as haematopoiesis, inflammation and immunity. It plays an oncogenic role in the 
pathogenesis of numerous cancers, including leukemia, breast cancer, colon cancer, 
lung cancer, and PDAC [116, 117]. Dr. Sen’s group found elevated expression levels 
of hsa-mir-155 in the plasma of PDAC patients as compared with plasma from healthy 
controls, suggesting that this miRNA may serve as a blood-based biomarker for the 
detection of PDAC [118]. This miRNA has also been reported as a biomarker of early 
pancreatic neoplasia [119]. 
In this study, using RPPA and IPA the evidence suggested that hsa-mir-155 
may impact the progression of PDAC not only through direct regulation of target 
genes, but also through a series of pathways and networks. Interestingly, several very 
important signaling pathways in PDAC were shown to be influenced by hsa-mir-155 
modulation in PDAC cell lines. Due to the limited number of validated antibodies in 
the RPPA experiment, not all genes that were affected by the upregulation of this 
miRNA could be detected. To validate the RPPA data, the variations of the protein 
expression need to be confirmed by Western blotting in future studies. 
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In conclusion, this study combined statistical analysis with biological 
approaches to determine the relationships between several miRNAs and the SEL1L 
gene. The finding that the expression of tumor suppressor SEL1L was repressed by the 
upregulation of hsa-mir-155 elucidated the mechanism for SEL1L downregulation in 
some PDAC cases. The findings provided evidence for using miRNAs as new 
approaches for the detection, prevention and treatment of this dismal disease.  
  
  
95 
SUMMARY AND FUTURE DIRECTIONS 
 
In this study, the aberrations of the putative tumor suppressor gene SEL1L in 
PDAC tumors were investigated. The goal was to determine the mechanism(s) of 
SEL1L downregulation. SEL1L downregulation was confirmed in a significant 
proportion of the tumors at both mRNA level and protein level. For the first time, 
abundant presence of variant splicing products of SEL1L were observed in PDAC, and 
for the first time LOH was detected in the SEL1L gene in 15.4% of the tumors. It was 
determined that mutations, LOH and promoter methylation are not the mechanisms of 
SEL1L downregulation. Data was generated demonstrating that overexpression of hsa-
mir-155 may cause SEL1L downregulation in some PDAC cases. It is possible that 
some other miRNAs that were not included in this study may target and repress SEL1L 
expression. No mutations were detected in the SEL1L coding region. As tumor 
suppressor genes generally follow the “two-hit hypothesis” [120], which implies that 
cancer is the result of accumulated mutations to a cell's DNA, although SEL1L has 
functions involving tumor suppression it cannot be identified as a classical tumor 
suppressor gene. 
The findings of the studies described in this thesis provide a better 
understanding of the abnormalities of the SEL1L gene in PDAC, which could lead to 
new approaches for the early detection, prevention and treatment of this dismal 
disease. Through these studies, besides having learned new techniques, I have 
expanded my knowledge and experience in problem solving, critical thinking and data 
analysis, as well as connecting laboratory findings to clinical information. However, 
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there are still many questions that remain as a result of my studies that lead to future 
studies.  
For the finding of variant splicing products of SEL1L, at this point it is not 
clear if these products are specifically associated with PDAC tumors since they were 
also observed in normal-appearing adjacent tissues. However, normal appearing tissue 
adjacent to the cancer in general is not normal even though the histological appearance 
may be normal. The “normal” tissues may display biomarkers that are found in the 
tumor due to underlying genetic events that they share with the tumor, but do not 
display all of the molecular features that the cancer has. This is called a field effect 
and has recently been reviewed by Chai and Brown [121]. As discussed in Chapter 1, 
to determine whether there are tumor-specific SEL1L transcripts in PDAC, further 
tests with microdissected tissues and deep sequencing are necessary. As mentioned 
above in Chapter 1, mis-splicing similar to what we have observed has been reported 
for other genes. So far, there is no reported explanation for this mis-splicing 
phenomenon. Future studies could examine several PDAC cell lines using RT-PCR 
and subcloning to see whether variant transcripts of SEL1L mRNA can be detected. 
This might allow us to determine if the variant transcripts arise clonally. If higher 
frequency of variant transcripts is observed in the PDAC cells than in the HPNE cells, 
DNA microarray could be performed to determine whether there are expression 
alterations in splicing machinery-related genes in the PDAC cells when compared to 
HPNE cells. If altered splicing machinery-related genes are identified, the next step 
would be to restore the normal expression of the gene and determine whether SEL1L 
splicing becomes normal.  
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In this study, it was determined that overexpression of hsa-mir-155 may be one 
of the factors that repress SEL1L expression, but it does not explain the abnormal 
expression of SEL1L in all of the PDAC samples. During the past several years, the 
miRNA databases have been expanding and many newly discovered miRNAs were 
not included in this study. Therefore it is possible that there are other miRNAs 
regulating SEL1L expression that we did not test. Also there are some other 
mechanisms of gene downregulation that were not studied. These should be 
investigated in the future, such as histone modification [122, 123] and pseudogene 
silencing [124-126].  
Another path of investigation of the SEL1L gene that might shed light on its 
role in pancreatic cancer is its association with other known signaling pathways. 
Overexpression of SEL1L in human PDAC cells increased the expression levels of 
Smad4, activin A, TIMP and PTEN, suggesting an interaction of SEL1L with the 
TGFβ and PTEN signaling pathways [30, 33]. The RPPA data presented in this thesis 
and IPA analysis indicate a possible interaction of SEL1L with the proteins in the “cell 
death, gene expression, organismal development” network. However, the RPPA 
results still need to be confirmed by Western analysis, and the most informative 
approach to pursue the elaboration of pathways that are influenced by SEL1L would 
be to develop a pancreas-specific knock-out mouse model. Using this kind of model, it 
would be possible to determine whether the mice develop pancreatic cancer, and 
whether the reported signaling pathways and networks are truly influenced. Some 
physiological conditions, such as glucose starvation or hypoxia, may need to be 
applied for the activation of the UPR/ERAD pathway. Since there are two distinct 
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directions of the UPR/ERAD pathway, the stimulation of this pathway should be 
quantitatively adjusted to control the amount of generated unfolded/misfolded 
proteins.  
Hopefully on the basis of the studies described in this thesis, future studies will 
build upon these findings in order to understand the pathogenesis of PDAC, and the 
further characterization of biomarkers for early detection and prevention of PDAC. 
This will put us one step closer to defeating this devastating disease. 
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